Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Mountainfield Venture Partners is a venture capital firm founded by a team with extensive experience in biopharmaceutical leadership. Established in the United States, the firm focuses on building new companies around development-stage drug candidates aimed at transforming patient care. Mountainfield specializes in forming companies around in-licensed drug candidates and assembling world-class leadership teams, supported by capital raises from top-tier life science institutional investors.
Currently, Mountainfield manages a portfolio of over 15 venture-backed life sciences companies, with a notable track record that includes six NASDAQ IPOs and eight FDA-approved drug products. The firm’s strategic approach to investment is rooted in its team's deep industry knowledge, which spans both small biotechnology startups and large pharmaceutical companies.
Mountainfield Venture Partners invests primarily in the biopharmaceutical sector, concentrating on development-stage drug candidates. The firm emphasizes the creation of companies that leverage in-licensed drug candidates, which allows them to capitalize on existing research and development efforts. Their investment strategy is informed by the extensive experience of their team, which includes professionals from both small startups and multinational pharmaceutical firms.
Mountainfield typically invests at the seed, Series A, and Series B stages, focusing on companies that are poised to make significant advancements in patient care. The firm seeks founders who demonstrate a strong vision and operational capabilities, as well as a commitment to addressing unmet medical needs.
Mountainfield Venture Partners has co-founded more than 15 venture-backed life sciences companies, leading to six NASDAQ IPOs and eight FDA-approved drug products. Notable companies in their portfolio include:
Daniel Curran, MD - Managing Partner. Dr. Curran has extensive experience in biopharmaceutical leadership and has played a pivotal role in the development of several successful life sciences companies.
David Socks - Managing Partner. Socks brings a wealth of knowledge in venture capital and has been instrumental in guiding portfolio companies through various stages of growth.
Siyu Shi, MD - Vice President. Dr. Shi specializes in biopharmaceutical investments and has a strong background in clinical development.
Christian Fougner, MD, PhD - Vice President. Dr. Fougner has expertise in drug development and regulatory affairs, contributing to the firm's strategic investment decisions.
Adam Ingber - Senior Associate. Ingber supports the investment team with market analysis and due diligence on potential portfolio companies.
To pitch Mountainfield Venture Partners, founders should use the contact form available on their website. It is advisable to include a detailed deck that outlines the business model, market opportunity, and operational strategy. Response times may vary, but direct outreach is encouraged for potential investment discussions.
In recent months, Mountainfield Venture Partners has continued to expand its portfolio, co-founding several new life sciences companies. Their notable track record includes leading six NASDAQ IPOs and supporting eight FDA-approved drug products.
The firm remains active in the biopharmaceutical sector, focusing on development-stage drug candidates and leveraging its extensive industry experience to guide new ventures.
What are Mountainfield's investment criteria?
Mountainfield Venture Partners invests in the biopharmaceutical sector, specifically targeting development-stage drug candidates. They focus on companies that leverage in-licensed drug candidates and demonstrate strong operational strategies.
How can I pitch to Mountainfield?
Founders can pitch to Mountainfield by visiting their contact page at Mountainfield Venture Partners Contact Page. They encourage direct outreach for potential investment opportunities.
What makes Mountainfield different from other VCs?
Mountainfield's unique approach lies in its focus on forming companies around in-licensed drug candidates, combined with the extensive biopharmaceutical experience of its team. This enables them to provide valuable insights and operational support to portfolio companies.
What is the geographic scope of Mountainfield's investments?
The firm primarily invests in companies based in the United States, focusing on the biopharmaceutical sector.
What is Mountainfield's post-investment involvement like?
Mountainfield actively participates in the development of its portfolio companies, often providing operational support and strategic guidance based on their team's extensive industry experience.
What is the typical check size for Mountainfield's investments?
While specific check sizes are not disclosed, Mountainfield typically invests at the seed, Series A, and Series B stages, indicating a range that aligns with early-stage funding needs.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.